Search Results - obesity

7 Results

Sort By:

Treatment of Post-menopausal Obesity and Associated Disease by PDE9 Inhibitors

Unmet NeedObesity is a serious health problem both globally and in the United States. Obesity is associated with numerous comorbidities including type-2 diabetes, cardiovascular disease, and certain types of cancers. In particular, obesity is commonly seen in the post-menopausal population as 74% of American women over the age of 60 are considered overweight....

Published: 3/14/2025 | Inventor(s): David Kass, Dong Ik Lee, Sumita Mishra

Keywords(s): Antagonists/Inhibitors, Disease Indication, Metabolic Disorders, Obesity, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Obesity

Supramolecular Hydrogel Applications to the Carotid Bodies to Treat Hypertension and Sleep Apnea in Obesity

Unmet NeedOver one-third of adults in the U.S. (36.5%) have obesity. Further, obesity leads to increased cardiovascular morbidity and mortality via multiple adverse mechanisms that include increased prevalence and severity of hypertension (often resistant to treatment) and obstructive sleep apnea (OSA). Currently, no pharmacotherapy exists for OSA....

Published: 3/13/2025 | Inventor(s): Vsevolod Polotsky, Honggang Cui, Roxana Mitrut, Mi-kyung Shin

Keywords(s): Cardiovascular Diseases, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Hypertension, Metabolic Disorders, Obesity, Peptides/Prodrugs, Sleep Apnea, Sleep Disorders, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Cardiovascular > Hypertension, Clinical and Disease Specializations > Sleep Disorders > Sleep Apnea, Clinical and Disease Specializations > Obesity

Compounds and Methods to Decrease Obesity-related Hepatic Fat Accumulation and Serum Glucose

Technology DescriptionResearchers at Johns Hopkins have identified that valproic acid (VPA) and its metabolites may be useful for the treatment of obesity and related metabolic diseases (e.g., type 2 diabetes, fatty liver disease).VPA and its cytochrome P450- and beta-oxidation-dependent metabolites activate AMP-activated protein kinase (AMPK), which...

Published: 3/13/2025 | Inventor(s): Lindsay Avery, Namandje Bumpus

Keywords(s): Agonists/Promoters, Disease Indication, Metabolic Disorders, Non-novel, Obesity, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Therapeutic Modalities

A Novel Obesity Model: Human Synphilin-1 Transgenic Mouse

Invention novelty: The technology is a transgenic mouse strain (SP1) utilizing synphilin-1 to control food intake and body weight thus providing a convenient model for obesity studies.Value Proposition: The technology provides a unique genetic obesity model for future studies of the pathogenesis of obesity and related disorders.Key features include:-...

Published: 3/13/2025 | Inventor(s): Christopher Ross, Timothy Moran, Wanli Smith

Keywords(s): Basic Research Biomarker, Discovery/Research Tools, Disease Indication, In Vivo Research Tool, Metabolic Disorders, Mouse Model, Mouse Model Xenograft, Obesity

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Research Tools > Animal Models, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Research Tools

12612 B6.129-Gria1/J; 12613 B6.129-Gria1/J; 12614 B6.129-Gria1/J; 12615 B6.129-Gria2/J; 12616 B6.129-Gria3/J; 12617 B6.129-Gria3tm2R1h/J; 12618 B6.129-Gria4/J; 12619 B6.129-Gria4tm1R1h/J

C11079: Transgenic Gria mouse strains.Value Proposition: Transgenic Gria mouse strains: • 12612 B6.129-Grial/J • 12613 B6.129-Grial/J • 12614 B6.129-Grial/J • 12615 B6.129-Gria2/J • 12616 B6.129-Gria3/J • 12617 B6.129-Gria3tm2Rlh/J • 12618 B6.129-Gria4/J • 12619 B6.129-Gria4tmlRlh/J Published...

Published: 3/13/2025 | Inventor(s): Richard Huganir

Keywords(s): Addiction, Basic Research Biomarker, Cell Lines, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, In Vivo Research Tool, Knock In Mouse Model, Metabolic Disorders, Mouse Cell Lines, Mouse Model, Obesity

Category(s): Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Obesity

Novel Protein Therapeutic for Diabetes and Obesity

Novelty: This technology identifies a novel myonectin protein, which links skeletal muscle to metabolic regulation. Myonectin was found to lower circulating free fatty acid levels by promoting lipid uptake. Value Proposition: Type-2 diabetes, obesity, and metabolic syndrome are diseases that dramatically reduce patient quality of life and lead...

Published: 3/13/2025 | Inventor(s): Marcus Seldin, Guang Wong

Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Obesity, Therapeutic Matter, Therapeutics, Type II Diabetes

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes

Germline and Conditional Deletion of Tardbp

C11168: A Gene Linked to Obesity, and Alters Body Fat Metabolism Value Proposition: • Identifies novel therapeutic target to control obesity and diabetes. • Helps to understand incurable diseases: frontal temporal dementia and amyotrophic lateral sclerosis. Technical Details: JHU scientists have developed conditional knockout mice...

Published: 3/13/2025 | Inventor(s): Donald Price, Po-Min Chiang, Philip Wong

Keywords(s): Amyotrophic Lateral Sclerosis, Basic Research Biomarker, Biomarker, Cell Model, Clinical Diagnostics, CNS and Neurological Disorders, Dementia, Diabetes, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics, In Vitro Research Tool, In Vivo Research Tool, Knock Out Mouse Model, Mechanism-of-action Biomarker, Metabolic Disorders, Mouse Model, Neurodegeneration, Obesity, Stem Cells

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Metabolic Diseases, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Stem Cells